Maravai Lifesciences Holdings (MRVI) Capital Expenditures (2020 - 2026)

Maravai Lifesciences Holdings' Capital Expenditures history runs 7 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 209.41% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $16.2 million, a 1718.92% increase from a year earlier, with the FY2025 full-year figure at $13.1 million, up 402.64% from the prior year.
• Capital Expenditures declined to $4.4 million in Q1 2026 per MRVI's latest filing, from $12.2 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $25.1 million in Q2 2023 and bottomed at -$46.7 million in Q4 2023.
• The 5-year median for Capital Expenditures is $4.4 million (2026), against an average of $1.4 million.
• Across the five-year window, Capital Expenditures soared 1697.01% in 2022 and slumped 409.46% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at -$9.2 million in 2022, then slumped by 409.46% to -$46.7 million in 2023, then jumped by 54.66% to -$21.2 million in 2024, then soared by 157.72% to $12.2 million in 2025, then tumbled by 63.73% to $4.4 million in 2026.
• Per Business Quant, the three latest MRVI Capital Expenditures figures stand at $4.4 million (Q1 2026), $12.2 million (Q4 2025), and -$7.2 million (Q3 2025).